At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Pepinemab +1 moredrug
Likely dose
Pepinemab 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-AD
In Brief
A Phase 2 clinical trial evaluating Pepinemab and Placebo for Alzheimer Disease. Completed, enrolled 50 participants across 14 sites.
Detailed Summary
To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsAlzheimer's Drug Discovery Foundation, Alzheimer's Association
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJul 2021
Primary CompletionJun 2024
TodayJul 2026
First PostedMay 8, 2020
Enrollment StartJul 22, 2021
Primary CompletionJun 5, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 6.1 years ago
Interventions
Pepinemabdrug
Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
Placebodrug
Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80